B-intervention	0	11	Palbociclib
O	11	12	:
O	13	14	A
O	15	20	Novel
O	21	27	Cyclin
O	27	28	-
O	28	37	Dependent
O	38	44	Kinase
O	45	54	Inhibitor
O	55	58	for
O	59	66	Hormone
O	67	75	Receptor
O	75	76	-
O	76	84	Positive
O	85	93	Advanced
O	94	100	Breast
O	101	107	Cancer
O	107	108	.

O	109	111	To
O	112	118	review
O	119	130	palbociclib
O	130	131	,
O	132	133	a
O	134	139	novel
O	140	145	small
O	145	146	-
O	146	154	molecule
O	155	164	inhibitor
O	165	167	of
O	168	174	cyclin
O	174	175	-
O	175	184	dependent
O	185	192	kinases
O	193	194	4
O	195	198	and
O	199	200	6
O	200	201	,
O	202	205	and
O	206	209	its
O	210	217	current
O	218	223	place
O	224	226	in
O	227	234	therapy
O	235	238	for
O	239	242	the
O	243	252	treatment
O	253	255	of
O	256	263	hormone
O	264	272	receptor
O	273	274	(
O	274	277	HMR
O	277	278	)
O	278	279	-
O	279	287	positive
O	287	288	,
O	289	294	human
O	295	304	epidermal
O	305	311	growth
O	312	318	factor
O	319	327	receptor
O	328	329	2
O	330	331	(
O	331	335	Her2
O	335	336	)
O	336	337	-
O	337	345	negative
O	346	354	advanced
O	355	361	breast
O	362	368	cancer
O	368	369	.

O	370	374	Four
O	375	380	phase
O	381	382	I
O	383	389	trials
O	389	390	,
O	391	392	2
O	393	398	phase
O	399	401	II
O	402	408	trials
O	408	409	,
O	410	413	and
O	414	415	1
O	416	421	phase
O	422	425	III
O	426	431	trial
O	432	436	were
O	437	447	identified
O	448	452	from
O	453	456	May
O	457	461	2004
O	462	464	to
O	465	468	May
O	469	473	2015
O	474	479	using
O	480	486	PubMed
O	486	487	,
O	488	496	American
O	497	504	Society
O	505	507	of
O	508	516	Clinical
O	517	525	Oncology
O	526	527	(
O	527	531	ASCO
O	531	532	)
O	533	542	abstracts
O	542	543	,
O	544	547	and
O	548	556	European
O	557	564	Society
O	565	567	of
O	568	575	Medical
O	576	584	Oncology
O	585	586	(
O	586	590	ESMO
O	590	591	)
O	592	601	abstracts
O	601	602	.

O	603	605	In
O	606	609	the
O	610	615	first
O	615	616	-
O	616	620	line
O	621	628	setting
O	628	629	,
O	630	633	the
O	634	639	phase
O	640	642	II
O	643	654	PALbociclib
O	654	655	:
O	656	663	Ongoing
O	664	670	trials
O	671	673	in
O	674	677	the
O	678	688	Management
O	689	691	of
O	692	698	breast
O	699	705	cAncer
O	706	707	(
O	707	713	PALOMA
O	713	714	)
O	714	715	-
O	715	716	1
O	717	722	trial
O	723	733	randomized
O	734	742	patients
O	743	745	to
O	746	753	receive
B-control	754	763	letrozole
I-control	764	769	alone
O	770	772	or
O	773	782	letrozole
O	783	787	plus
O	788	799	palbociclib
O	800	803	125
O	804	806	mg
O	807	812	daily
O	813	816	for
O	817	818	3
O	819	824	weeks
O	824	825	,
O	826	834	followed
O	835	837	by
O	838	839	1
O	840	844	week
O	845	848	off
O	848	849	,
O	850	852	as
O	853	860	initial
O	861	868	therapy
O	869	872	for
O	873	881	advanced
O	882	888	breast
O	889	895	cancer
O	895	896	.

O	897	900	The
O	901	913	investigator
O	913	914	-
O	914	922	assessed
B-outcome	923	929	median
I-outcome	930	941	progression
I-outcome	941	942	-
I-outcome	942	946	free
I-outcome	947	955	survival
I-outcome	956	957	(
I-outcome	957	960	PFS
I-outcome	960	961	)
O	962	965	was
B-iv-cont-median	966	968	20
I-iv-cont-median	968	969	.
I-iv-cont-median	969	970	2
I-iv-cont-median	971	977	months
O	978	981	for
O	982	985	the
O	986	997	combination
O	998	1004	versus
B-cv-cont-median	1005	1007	10
I-cv-cont-median	1007	1008	.
I-cv-cont-median	1008	1009	2
I-cv-cont-median	1010	1016	months
O	1017	1020	for
O	1021	1030	letrozole
O	1031	1036	alone
O	1037	1038	(
O	1038	1044	hazard
O	1045	1050	ratio
O	1051	1052	[
O	1052	1054	HR
O	1054	1055	]
O	1056	1057	=
O	1058	1059	0
O	1059	1060	.
O	1060	1063	488
O	1063	1064	;
O	1065	1067	95
O	1067	1068	%
O	1069	1071	CI
O	1072	1073	=
O	1074	1075	0
O	1075	1076	.
O	1076	1079	319
O	1079	1080	-
O	1080	1081	0
O	1081	1082	.
O	1082	1085	748
O	1085	1086	;
O	1087	1088	1
O	1088	1089	-
O	1089	1094	sided
O	1095	1096	P
O	1097	1098	=
O	1099	1100	0
O	1100	1101	.
O	1101	1105	0004
O	1105	1106	)
O	1106	1107	.

O	1108	1111	The
O	1112	1119	ensuing
O	1120	1124	Food
O	1125	1128	and
O	1129	1133	Drug
O	1134	1148	Administration
O	1149	1157	approval
O	1158	1160	of
O	1161	1172	palbociclib
O	1173	1176	was
O	1177	1182	given
O	1183	1184	a
O	1185	1186	"
O	1186	1198	breakthrough
O	1199	1206	therapy
O	1206	1207	"
O	1208	1219	designation
O	1219	1220	,
O	1221	1226	where
O	1227	1238	preliminary
O	1239	1247	evidence
O	1248	1256	suggests
O	1257	1268	substantial
O	1269	1280	improvement
O	1281	1285	over
O	1286	1294	existing
O	1295	1304	therapies
O	1305	1308	for
O	1309	1310	a
O	1311	1318	serious
O	1319	1321	or
O	1322	1326	life
O	1326	1327	-
O	1327	1338	threatening
O	1339	1346	disease
O	1346	1347	.

O	1348	1349	A
O	1350	1362	confirmatory
O	1363	1368	phase
O	1369	1372	III
O	1373	1378	trial
O	1378	1379	,
O	1380	1386	PALOMA
O	1386	1387	-
O	1387	1388	2
O	1388	1389	,
O	1390	1392	is
O	1393	1398	under
O	1399	1402	way
O	1402	1403	.

O	1404	1406	In
O	1407	1415	patients
O	1416	1419	who
O	1420	1424	were
O	1425	1435	previously
O	1436	1443	treated
O	1444	1448	with
O	1449	1458	endocrine
O	1459	1466	therapy
O	1467	1470	for
O	1471	1479	advanced
O	1480	1486	breast
O	1487	1493	cancer
O	1493	1494	,
O	1495	1498	the
O	1499	1504	phase
O	1505	1508	III
O	1509	1515	PALOMA
O	1515	1516	-
O	1516	1517	3
O	1518	1523	trial
O	1524	1534	randomized
O	1535	1543	patients
O	1544	1546	to
O	1547	1558	fulvestrant
O	1559	1563	plus
O	1564	1575	palbociclib
O	1576	1582	versus
B-control	1583	1594	fulvestrant
I-control	1595	1599	plus
I-control	1600	1607	placebo
O	1607	1608	.

O	1609	1612	The
O	1613	1625	investigator
O	1625	1626	-
O	1626	1634	assessed
B-outcome	1635	1641	median
I-outcome	1642	1645	PFS
I-outcome	1646	1648	at
I-outcome	1649	1652	the
I-outcome	1653	1657	time
I-outcome	1658	1660	of
I-outcome	1661	1662	a
I-outcome	1663	1673	preplanned
I-outcome	1674	1682	analysis
O	1683	1686	was
B-iv-cont-median	1687	1688	9
I-iv-cont-median	1688	1689	.
I-iv-cont-median	1689	1690	2
I-iv-cont-median	1691	1697	months
O	1698	1702	with
O	1703	1714	palbociclib
O	1714	1715	-
O	1715	1726	fulvestrant
O	1727	1735	compared
O	1736	1740	with
B-cv-cont-median	1741	1742	3
I-cv-cont-median	1742	1743	.
I-cv-cont-median	1743	1744	8
I-cv-cont-median	1745	1751	months
O	1752	1756	with
O	1757	1764	placebo
O	1764	1765	-
O	1765	1776	fulvestrant
O	1777	1778	(
O	1778	1780	HR
O	1781	1782	=
O	1783	1784	0
O	1784	1785	.
O	1785	1787	42
O	1787	1788	;
O	1789	1791	95
O	1791	1792	%
O	1793	1795	CI
O	1796	1797	=
O	1798	1799	0
O	1799	1800	.
O	1800	1802	32
O	1802	1803	-
O	1803	1804	0
O	1804	1805	.
O	1805	1807	56
O	1807	1808	;
O	1809	1810	P
O	1811	1812	<
O	1813	1814	0
O	1814	1815	.
O	1815	1818	001
O	1818	1819	)
O	1819	1820	.

O	1821	1832	Palbociclib
O	1832	1833	,
O	1834	1837	the
O	1838	1843	first
O	1843	1844	-
O	1844	1846	in
O	1846	1847	-
O	1847	1852	class
O	1853	1857	CDK4
O	1857	1858	/
O	1858	1859	6
O	1860	1869	inhibitor
O	1869	1870	,
O	1871	1884	significantly
O	1885	1893	extended
O	1894	1897	PFS
O	1898	1900	in
O	1901	1912	combination
O	1913	1917	with
O	1918	1927	endocrine
O	1928	1935	therapy
O	1936	1938	in
O	1939	1942	the
O	1943	1948	first
O	1949	1952	and
O	1953	1963	subsequent
O	1964	1969	lines
O	1970	1972	of
O	1973	1982	treatment
O	1983	1986	for
O	1987	1990	HMR
O	1990	1991	-
O	1991	1999	positive
O	1999	2000	,
O	2001	2005	Her2
O	2005	2006	-
O	2006	2014	negative
O	2015	2023	advanced
O	2024	2030	breast
O	2031	2037	cancer
O	2037	2038	.
